Abstracts Archive - Page 314 of 2607 - ACR Meeting Abstracts

Abstract Number: 2687 • ACR Convergence 2024
Therapeutic Choices in Systemic Sclerosis Associated Interstitial Lung Disease, a Survey of International Experts
Michael Macklin¹, Iazsmin Bauer Ventura¹ and Dinesh Khanna², ¹University of Chicago, Chicago, IL, ²University of Michigan, Ann Arbor, MI
Background/Purpose: The therapeutic options for systemic sclerosis-associated interstitial lung disease (SSc-ILD) have evolved rapidly, with recent guidelines released by the ACR and American Thoracic Society…
Abstract Number: 2683 • ACR Convergence 2024
Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries
Pavel Nikitin¹, Harshdeep Chawla¹, Manmohan Singh¹, Samuel Theodore², Salavat Aglyamov¹, Meng Zhang², Brian Skaug², Maureen Mayes², Kirill Larin¹ and Shervin Assassi², ¹University of Houston, Houston, TX, ²UTHealth Houston Division of Rheumatology, Houston, TX
Background/Purpose: Vascular involvement is a prominent feature of systemic sclerosis (SSc). Safe and non-invasive methods to visualize cutaneous blood vessels beyond nailfold capillaries are lacking.…
Abstract Number: PP12 • ACR Convergence 2024
Healing Together: The Role of Black, Indigenous and People of Color (BIPOC) -Only Chronic Illness Spaces in Comprehensive Care
Sarah Shaw and JP Summers, Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: As someone from the Black, Indigenous, and People of Color (BIPOC) community living with rheumatic conditions, I have experienced firsthand many challenges that people…
Abstract Number: PP10 • ACR Convergence 2024
Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally
Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY
Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…
Abstract Number: PP06 • ACR Convergence 2024
Sweat It Out: How the Sauna Has Helped Me Cope with Rheumatoid Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Since receiving my rheumatoid arthritis (RA) diagnosis in 2015, I have found that one of my top five strategies to manage my symptoms is spending…
Abstract Number: 2684 • ACR Convergence 2024
Assessment of Skin in Patients with Systemic Sclerosis Using High Frequency Ultrasound : A Comparative Study with Histology and Clinical Parameters of Skin Disease
Ruhani Desai¹, Filemon Tan², Minghua Wu³, Jefferey Browning⁴, Samuel Theodore³, Meng Zhang³, Brian Skaug³, Maureen Mayes³ and Shervin Assassi³, ¹UTHealth Houston Division of Rheumatology, DeLand, FL, ²University of Texas at Houston McGovern Medical School, Houston, TX, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴Boston Univeristy, Boston, MA
Background/Purpose: The extent of skin involvement and its rate of progression can provide prognostic information for systemic sclerosis (SSc)-related morbidity and mortality. Moreover, skin assessment…
Abstract Number: 2674 • ACR Convergence 2024
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States
christina Charles-Schoeman¹, Patrick Zueger², Erin Blondell², Siran Fang², Yi Peng², Manish Jain³ and John Tesser⁴, ¹UCLA Medical Center, Santa Monica, CA, ²AbbVie Inc, North Chicago, IL, ³Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, ⁴Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ
Background/Purpose: For patients with rheumatoid arthritis (RA), current ACR guidelines recommend evaluating treatment response within 3 months of initiating a new therapy. In patients who…
Abstract Number: 2686 • ACR Convergence 2024
Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
David Fox¹, Laura Cooney², Lia Stelzig³, Robert Lafyatis⁴, Johann Gudjonsson⁵, Lam Tsoi⁶, Maureen Mayes⁷, Ankoor Shah⁸, Suzanne Kafaja⁹, William Barry³, Ellen Goldmuntz¹⁰, Dawn Smilek¹¹ and Dinesh Khanna⁶, ¹University of Michigan, Dexter, MI, ²University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ³Rho, Durham, NC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, MI, ⁷UTHealth Houston Division of Rheumatology, Houston, TX, ⁸Duke University, Durham, NC, ⁹Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ¹⁰Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, ¹¹Immune Tolerance Network, UCSF, San Francisco, CA
Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…
Abstract Number: 2690 • ACR Convergence 2024
ANCA IgG Promotion of Neutrophil Recruitment, Migration and Vascular Damage in ANCA Associated Vasculitis May Be Enhanced by Hypoxia
Noelle Pisacano, Amrita Dhutia, Stephen Rothery, Charles Pusey, Edwin Chilvers, Andrew Cowburn, Katharine Lodge and Maria Prendecki, Imperial College London, London, United Kingdom
Background/Purpose: Neutrophils are main mediators of disease in ANCA associated vasculitis (AAV). Pathogenic ANCA IgG on neutrophils promotes neutrophil adhesion and migration at the endothelium.…
Abstract Number: PP04 • ACR Convergence 2024
Involving Pediatric Patients in Their Own Care
Whitney LaBar, Lupus and Allied Diseases Association, Pleasanton, CA
Background/Purpose: When I was 14, I was diagnosed with thrombocytopenia, which led to more testing and a diagnosis of systemic lupus erythematosus (SLE). As a…
Abstract Number: PP08 • ACR Convergence 2024
Whispers of Resilience: Navigating Life with Rheumatism
Vinchelle Hardison and Vinchelle Hardison, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: “What’s wrong with me mom? Why am I always slow and hurting? Why can’t I play without being in pain like the other kids?”…
Abstract Number: 2689 • ACR Convergence 2024
Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis
Lynn Fussner¹, Ivan Bilic², Carol McAlear³, David Cuthbertson⁴, Jie Cheng⁵, Elise Chen⁵, Markus Weiller², Ulrich Specks⁶ and Peter Merkel³, and for the Vasculitis Clinical Research Consortium, ¹The Ohio State University, Columbus, OH, ²Takeda Pharmaceuticals, Vienna, Austria, ³University of Pennsylvania, Philadelphia, PA, ⁴University of South Florida, Tampa, FL, ⁵Takeda Pharmaceuticals, Cambridge, MA, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
Abstract Number: 2693 • ACR Convergence 2024
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Ellen Romich¹, Joshua Baker², Ian Green², Rennie Rhee², Carol McAlear², Ulrich Specks³, Rona Smith⁴, David Jayne⁴ and Peter Merkel², and the RITAZAREM Investigators, ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, MN, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses are common in ANCA-associated vasculitis (AAV), both i) during maintenance treatment after induction of remission, and ii) after immunosuppressive treatment is discontinued. Relapses…
Abstract Number: 2692 • ACR Convergence 2024
Transcriptomic Profiling of Kidney Biopsies Implicates Th17 and IL-17 in ANCA-Associated Vasculitis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan⁴, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Brad Rovin³, Samir Parikh⁵, Stacy Ardoin⁶, Daniel Koboldt⁷, James Fitch⁷ and Salem Almaani⁸, ¹Nationwide, Columbus, OH, ²Feinstein Institutes for Medical Research, Melrose, MA, ³The Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, ⁵Ohio State University, Columbus, OH, ⁶Nationwide Children's Hospital, Columbus, OH, ⁷Steve and Cindy Rasmussen Institute for Genomic Medicine, Columbus, OH, ⁸The Ohio State University Medical Center, Columbus, OH
Background/Purpose: ANCA-associated vasculitis (AAV) is a severe autoimmune disease targeting small vessels, with significant kidney involvement. Despite current therapies, up to 28% of patients progress…
Abstract Number: 0166 • ACR Convergence 2024
Limitations in Activities of Daily Living Among Individuals with SLE
Laura Plantinga¹, Jinoos Yazdany², Courtney Hoge³, Charmayne M. Dunlop-Thomas⁴ and Patti Katz⁵, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁵UCSF, San Rafael, CA
Background/Purpose: A better understanding of the capacity of individuals with SLE to perform routine daily life tasks is needed to effectively support the independence and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].